Study Finds Strong Connection Between OSA and MASLD in Type 2 Diabetes Patients

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-07-21 03:15 GMT   |   Update On 2025-07-21 04:01 GMT
Advertisement

China: A recent study published in Scientific Reports has identified a strong link between obstructive sleep apnea (OSA) and metabolic dysfunction-associated steatotic liver disease (MASLD) among individuals with type 2 diabetes mellitus (T2DM). The findings highlight the importance of early detection and management of both conditions to prevent further health complications.

The study conducted by Dr. Qiang Lu and colleagues from the Department of Endocrinology at the First Hospital of Qinhuangdao, China, evaluated hospitalized T2DM patients using polysomnography to diagnose OSA and ultrasound imaging to assess the presence and severity of MASLD. Researchers also recorded relevant patient characteristics, including age, sex, diabetes duration, lifestyle habits (smoking and alcohol use), BMI, blood glucose, and lipid levels.

OSA severity was determined using the apnea-hypopnea index (AHI), while additional indicators such as the oxygen desaturation index (ODI) and the lowest oxygen saturation (LSaO2) during sleep were also considered.

The following were the key findings:

  • A high prevalence (64.4%) of coexisting obstructive sleep apnea (OSA) and metabolic dysfunction-associated steatotic liver disease (MASLD) was observed among participants.
  • All patients with severe MASLD were found to have OSA, with 50% exhibiting moderate or severe forms of the condition.
  • The severity of MASLD increased in parallel with the severity of OSA.
  • Nearly 92% of individuals with moderate-to-severe OSA had moderate-to-severe MASLD.
  • The higher apnea-hypopnea index (AHI) and oxygen desaturation index (ODI), along with lower lowest oxygen saturation (LSaO2), were strongly associated with more severe MASLD.
  • Among patients with moderate-to-severe MASLD, 62.5% had elevated AHI, 58.5% had reduced LSaO2, and 57.2% had high ODI values.
  • The association between OSA and MASLD severity remained significant even after adjusting for age, sex, BMI, and metabolic factors.
  • Researchers proposed that OSA may worsen liver disease progression in diabetic patients due to intermittent hypoxia and metabolic disruption.
  • The presence of MASLD may also contribute to the worsening of sleep-related breathing disorders.
Advertisement

“Our findings highlight the bidirectional relationship between OSA and MASLD in individuals with type 2 diabetes,” the authors stated. “This calls for routine screening of MASLD in OSA patients and vice versa, particularly in those with diabetes, to allow timely intervention.”

"Given the progressive nature of both conditions and their shared metabolic pathways, we strongly recommend timely and comprehensive screening for each condition in patients diagnosed with the other. Early identification through tools such as polysomnography and liver imaging—even in the absence of symptoms—can play a crucial role in preventing long-term systemic complications and improving overall patient outcomes,” the authors concluded.

Reference:

Jia, X., Zou, C., Lu, N., Lu, Q., & Xie, C. (2025). Obstructive sleep apnea is ralated to metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus. Scientific Reports, 15(1), 1-9. https://doi.org/10.1038/s41598-025-09985-x


Tags:    
Article Source : Scientific Reports

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Medical Bulletin 21/July/2025